AIxMed, a provider of an AI-powered computational platform for cytology applications, and Lumea have partnered to integrate AIxMed’s AI technology into Lumea’s digital pathology platform.
The collaboration aims to enhance diagnostic tools available to the urology market by incorporating AIxMed’s AIxURO solution.
AIxURO is designed to assist in analysing non-invasive urine cytology specimens to improve diagnostic accuracy and workflow efficiency in bladder cancer assessments.
It identifies suspicious and atypical cells using The Paris System for Reporting Urinary Cytology, supporting clinical decision-making and potentially reducing the need for invasive procedures like cystoscopies.
AIxMed CEO Samuel Chen said: “We recognise Lumea as a leader in providing an end-to-end solution for the urology market.
“We are excited to provide an integrated and tested solution within their platform allowing our mutual customers the ability to triage their cases, improve their QC, and make their work more efficient.”
Lumea CEO James Thackeray said: “We are pleased to partner with AIxMed and add their expertise in urine cytology AI to our growing portfolio of AI solutions.
“This partnership reflects our ongoing commitment to integrating valuable AI capabilities that meet the specific needs of our diverse customer base and enhance diagnostic pathways.”
Lumea plans to incorporate AIxURO into its digital pathology ecosystem, which is widely used by the US urology market. The integration will diversify Lumea’s offerings for urologists and strengthen support for comprehensive cancer diagnostic workflows.
In another development, AIxMed and CorePlus entered a Memorandum of Understanding to evaluate a Quality Control workflow solution for urine cytology.
The partnership aims to demonstrate the integration of AI into the urine cytology workflow, enhancing diagnostic consistency and efficiency.
AIxMed’s expertise in AI-based cytology software will combine with CorePlus’ experience in integrating digital and AI solutions into pathology workflows.
The collaboration seeks to provide an end-to-end solution for research-use-only cytology analysis, showcasing the potential for AI to improve diagnostic processes in medical settings.
CorePlus founder and CEO Mariano de Socarraz said: “AIxURO offers significant time savings with consistent results. Integrating our scanner with real-time AI-based QC checks significantly improves efficiency and diagnostic accuracy. Precision cytology is no longer a vision—it’s reality.”
